Can-Fite BioPharma Ltd. (CANF)
+0.143 (6.37%)
May 17, 2024, 4:00 PM EDT - Market closed

Company Description

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.

The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.

It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.

In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.

The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001.

The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Can-Fite BioPharma Ltd.
Can-Fite BioPharma logo
Country Israel
Founded 1994
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Motti Farbstein

Contact Details

26 Ben Gurion Street
Ramat Gan, L3 5257346
Phone 972 39241114

Stock Details

Ticker Symbol CANF
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001536196
CUSIP Number 13471N201
ISIN Number US13471N3008
SIC Code 2834

Key Executives

Name Position
Dr. Pnina Fishman Ph.D. Founder, Chief Scientific Officer and Executive Chairperson
Motti Farbstein Chief Executive Officer and Chief Financial and Operating Officer
Dr. Sari Fishman Ph.D. Vice President of Business Development
Dr. Ilan Cohn Ph.D. Co-Founder and Director
Dr. Stephen A. Harrison FACP, M.D. Member of Clinical Advisory Board and Consulting Chief Medical Officer

Latest SEC Filings

Date Type Title
May 13, 2024 6-K Report of foreign issuer
May 9, 2024 6-K Report of foreign issuer
May 6, 2024 6-K Report of foreign issuer
Apr 25, 2024 6-K Report of foreign issuer
Apr 15, 2024 6-K Report of foreign issuer
Apr 9, 2024 EFFECT Notice of Effectiveness
Apr 5, 2024 S-8 Securities to be offered to employees in employee benefit plans
Apr 5, 2024 POS AM Post-Effective amendments for registration statement
Apr 3, 2024 6-K Report of foreign issuer
Mar 28, 2024 20-F Annual and transition report of foreign private issuers